Rapamycin resolves genetic defects in yeast

April 13, 2018, Okinawa Institute of Science and Technology
Dr. Kenicki Sajiki (Right) and technician Yuria Tahara at work in the lab. Credit: OIST

Scientists at the Okinawa Institute of Science and Technology Graduate University (OIST) have taken one step closer to potential cures for several human genetic diseases, and the answers have been found in the humble cells of fission yeast.

Dr. Kenichi Sajiki and the team in Prof. Mitsuhiro Yanagida's G0 Cell Unit at OIST have determined that , a biological compound produced by bacteria, is able to "rescue" with genetic defects and maintain normal cell function. Their work was published in Open Biology.

Rapamycin is already in common use throughout the medical world as an immunosuppressant. As such, it is commonly prescribed to patients undergoing kidney transplants to prevent rejection of the new organs. It is also routinely used for cancer treatments, as well as for coating coronary stents. Rapamycin has also produced extended lifespan in mouse cells.

The OIST team has uncovered a new side to rapamycin, paving the way to new medical therapies for genetic diseases.

"This is the first systematic screen to find mutants that can be cured by the drug. Previously, we knew chromosome diseases were cured by the same drug. Now, Sajiki and more than 10 authors discovered 12 more yeast gene diseases curable with rapamycin," says Prof. Yanagida.

Mutant fission yeast (left) were restored to normal function (right) after treatment with rapamycin. Credit: OIST

Rapamycin inhibits cell growth and division—known as proliferation—by regulating the function of TOR Kinase, a main signaling enzyme that conveys information to the cell about nutritional conditions. The team hypothesized that if rapamycin could restore normal proliferation in cells with mutated DNA, it was possible that the affected genes conserved in humans responsible for could potentially be treated by rapamycin.

The team devised an experiment using fission , each of which had a specific mutation in their DNA that created cell division defects when exposed to raised temperatures of 36°C. The researchers tested a library of 1014 mutant strains of yeast. 45 of the mutants were "rescued" by rapamycin addition and began to divide normally once again.

Analyzing the genetic makeup of the rescued yeast cells, the lab team identified 12 genes that were responsible for the temperature-triggered defects. With the source identified, the team now knew where to look for the answer to rapamycin's restorative properties.

The genes are involved with four cellular function groups. One controls stress response signaling by creating a type of enzyme called stress activated protein kinase (SAPK). Left alone, mutated versions of these genes created SAPKs that were responsible for the malfunctions in experimental yeast cells, again causing abnormal cell growth and division.

Rapamycin maintains the balance of the kinases SAPK and TOR to ensure cells grow and divide normally. Credit: OIST

Adding rapamycin returned these cells to normal function. The scientists observed that rapamycin essentially overrides the aberrant behavior of SAPK mutation so that resulting biochemical production is maintained at normal levels. This controls a delicate balance between SAPK and TOR Kinase that is key to keeping cells growing and dividing normally. Further groups of genes affected by rapamycin in this way include those responsible for cellular functions such as the exchange of chemicals between cells and the regulation of the genetic compound chromatin's structure.

The study is a first step in opening new avenues of research that could lead to cures for debilitating genetic conditions like Cornelia de Lange syndrome and cognitive development disorders. Their identification of the method through which rapamycin works adds a critical new dimension to this already highly useful chemical: "We hope this research will give a new insight into how we can apply rapamycin in the future," says Dr. Sajiki.

Explore further: Lifespan prolonged by inhibiting common enzyme

More information: Kenichi Sajiki et al, Genetic defects in SAPK signalling, chromatin regulation, vesicle transport and CoA-related lipid metabolism are rescued by rapamycin in fission yeast, Open Biology (2018). DOI: 10.1098/rsob.170261

Related Stories

Study reveals how cancer drug causes diabetic-like state

April 3, 2012

Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.

Tubules to stop cell growth

October 4, 2017

TORC1 is an enzyme complex that controls the normal growth of cells. However, when it is too active, it can promote diseases such as cancer. A study led by biologists from the University of Geneva (UNIGE), Switzerland, and ...

Red wine compound increases anti-tumor effect of rapamycin

February 14, 2011

Cleveland – Researchers from Cleveland Clinic's Lerner Research Institute have discovered that resveratrol – a compound found in red wine – when combined with rapamycin can have a tumor-suppressing effect on ...

Recommended for you

EPA adviser is promoting harmful ideas, scientists say

March 22, 2019

The Trump administration's reliance on industry-funded environmental specialists is again coming under fire, this time by researchers who say that Louis Anthony "Tony" Cox Jr., who leads a key Environmental Protection Agency ...

Coffee-based colloids for direct solar absorption

March 22, 2019

Solar energy is one of the most promising resources to help reduce fossil fuel consumption and mitigate greenhouse gas emissions to power a sustainable future. Devices presently in use to convert solar energy into thermal ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.